THE HISTONE DEACETYLASE INHIBITOR ITF2357 (GIVINOSTAT) PROMOTES BURKITT'S LYMPHOMA CELL LINE DEATH MODULATING MICRO-RNA AND TISSUE TRANSGLUTAMINASE 2 EXPRESSION

被引：0
|
作者：
Zappasodi, R. [1 ]
Di Nicola, M. [1 ]
Carlo-Stella, C. [2 ]
Baldan, F. [1 ]
Iorio, M. V. [1 ]
Magni, M. [1 ]
Tagliabue, E. [1 ]
Croce, C. M. [3 ]
Gianni, A. M. [1 ]
机构：
[1] Ist Nazl Tumori, I-20133 Milan, Italy
[2] Univ Milan, Milan, Italy
[3] Ohio State Univ, Columbus, OH 43210 USA
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0674
引用
收藏
页码：275 / 275
页数：1
相关论文
共 16 条
  • [1] The histone deacetylase inhibitor ITF2357 (Givinostat) promotes Burkitt's lymphoma cell line death modulating micro-RNA and tissue transglutaminase 2 expression
    Di Nicola, Massimo
    Zappasodi, Roberta
    Baldan, Francesca
    Lorio, Marilena
    Magni, Michele
    Tagliabue, Elda
    Carlo-Stella, Carmelo
    Croce, Carlo
    Gianni, Alessandro
    CANCER RESEARCH, 2009, 69
  • [2] Cytotoxic Activity of Histone Deacetylase Inhibitor ITF2357 on Burkitt's Lymphoma Cell Lines Is Associated to Micro-RNA Modulation and Transglutaminase 2 Restoration
    Zappasodi, Roberta
    Di Nicola, Massimo
    Baldan, Francesca
    Iorio, Marilena V.
    Magni, Michele
    Tagliabue, Elda
    Croce, Carlo M.
    Carlo-Stella, Carmelo
    Gianni, Alessandro M.
    BLOOD, 2008, 112 (11) : 565 - 565
  • [3] Chemosensitization and radiosensitization effects of glioblastoma cells by the histone deacetylase inhibitor, givinostat (ITF2357) in glioblastoma cell models
    Gravina, G. L.
    Leoni, F.
    Benedetti, E.
    Delle Monache, S.
    Mancini, A.
    Angelucci, A.
    Di Cesare, E.
    Cimini, A. M.
    Porro, G.
    Festuccia, C.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S211 - S211
  • [4] Role of the Histone Deacetylase Inhibitor Givinostat (ITF2357) in Treatment of CRLF2 Rearranged Acute Lymphoblastic Leukemia
    Savino, Angela Maria
    Sarno, Jolanda
    Trentin, Luca
    Vieri, Margherita
    Fazio, Grazia
    Bardini, Michela
    Bugarin, Cristina
    Fossati, Gianluca
    Davis, Kara L.
    Gaipa, Giuseppe
    Meyer, Lueder Hinrich
    Nolan, Garry P.
    Biondi, Andrea
    Kronnie, Geertruy Te
    Palmi, Chiara
    Cazzaniga, Giovanni
    BLOOD, 2015, 126 (23)
  • [5] MiR-146a up-Regulation Is Associated with Anti-Tumor Activity of Pan-Histone Deacetylase Inhibitor ITF2357 (Givinostat®) in Human Burkitt's Lymphoma
    Zappasodi, Roberta
    Cavane, Alessandra
    Iorio, Marilena V.
    Tortoreto, Monica
    Ruggiero, Giusi
    Magni, Michele
    Carlo-Stella, Carmelo
    Tagliabue, Elda
    Zunino, Franco
    Croce, Carlo M.
    Gianni, Alessandro M.
    Di Nicola, Massimo
    BLOOD, 2011, 118 (21) : 1174 - 1174
  • [6] The Histone Deacetylase Inhibitor ITF2357 (Givinostat) Targets Oncogenic BRAF in Melanoma Cells and Promotes a Switch from Pro-Survival Autophagy to Apoptosis
    Celesia, Adriana
    Notaro, Antonietta
    Franzo, Marzia
    Lauricella, Marianna
    D'Anneo, Antonella
    Carlisi, Daniela
    Giuliano, Michela
    Emanuele, Sonia
    BIOMEDICINES, 2022, 10 (08)
  • [7] Phase II study of the histone-deacetylase inhibitor ITF2357 in relapsed/refractory Hodgkin's lymphoma patients
    Viviani, S.
    Bonfante, V.
    Fasola, C.
    Valagussa, P.
    Gianni, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] THE HISTONE DEACETYLASE INHIBITOR GIVINOSTAT (ITF2357) HAS A POTENT ANTI-TUMOR ACTIVITY AGAINST CRLF2 REARRANGED LEUKEMIA
    Savino, A. M.
    Sarno, J.
    Trentin, L.
    Vieri, M.
    Fazio, G.
    Bardini, M.
    Bugarin, C.
    Fossati, G.
    Davis, K.
    Gaipa, G.
    Meyer, L.
    Nolan, G.
    Biondi, A.
    te Kronnie, T.
    Palmi, C.
    Cazzaniga, G.
    HAEMATOLOGICA, 2016, 101 : 198 - 198
  • [9] The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL
    A M Savino
    J Sarno
    L Trentin
    M Vieri
    G Fazio
    M Bardini
    C Bugarin
    G Fossati
    K L Davis
    G Gaipa
    S Izraeli
    L H Meyer
    G P Nolan
    A Biondi
    G Te Kronnie
    C Palmi
    G Cazzaniga
    Leukemia, 2017, 31 : 2365 - 2375
  • [10] The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL
    Savino, A. M.
    Sarno, J.
    Trentin, L.
    Vieri, M.
    Fazio, G.
    Bardini, M.
    Bugarin, C.
    Fossati, G.
    Davis, K. L.
    Gaipa, G.
    Izraeli, S.
    Meyer, L. H.
    Nolan, G. P.
    Biondi, A.
    Kronnie, G. Te
    Palmi, C.
    Cazzaniga, G.
    LEUKEMIA, 2017, 31 (11) : 2365 - 2375
12